Exelixis Entered into an Option and License Agreement with BioInvent to Develop Novel Antibody-Based Immuno-Oncology Therapies
Shots:
- BioInvent to receive $25M up front in exchange for rights to select 3 targets which were identified by BioInvent’s F.I.R.S.T platform & n-CoDeR library & is eligible to receive option exercise fee, success-based milestones along with royalties
- BioInvent will lead the future development, commercialization & other activities for the development candidate. Exelixis will be granted the option to in-license target programs upon the identification of a development candidate directed toward that target
- The collaboration will broaden Exelixis' portfolio of Ab-based therapies & combine BioInvent's expertise with Exelixis' expertise & resources in Ab engineering & ADC technologies to develop & commercialize cancer therapies
Ref: Bussinesswire | Image: Exelixis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
